UP!
Biota was an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.
In November 2012, Biota Holdings Limited merged with American company Nabi Biopharmaceuticals to form Biota Pharmaceuticals.
The combined company has its headquarters in the U.S. and is now listed on the NASDAQ under the abbreviated code BOTA.
| 2016-03-18 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-02-08 | Reiterated Rating | FBR & Co. | Outperform | $6.00 |
| 2016-01-27 | Reiterated Rating | FBR & Co. | Outperform | $6.00 |
| 2016-01-27 | Initiated Coverage | HSBC | Buy | |
| 2016-01-26 | Initiated Coverage | FBR & Co. | Buy | |
| 2015-12-28 | Initiated Coverage | FBR & Co. | Buy | |
| 2015-12-22 | Initiated Coverage | FBR & Co. | Outperform | $6.00 |
| 2014-08-04 | Downgrade | Guggenheim | Buy to Neutral | $5.00 to $3.00 |
| 1970-01-01 |
| 2016-03-18 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-02-08 | Reiterated Rating | FBR & Co. | Outperform | $6.00 |
| 2016-01-27 | Reiterated Rating | FBR & Co. | Outperform | $6.00 |
| 2016-01-27 | Initiated Coverage | HSBC | Buy | |
| 2016-01-26 | Initiated Coverage | FBR & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In BOTA 1 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Dominick & Dominick LLC | 0.15M |
UM